Matches in Wikidata for { <http://www.wikidata.org/entity/Q65345564> ?p ?o ?g. }
Showing items 1 to 53 of
53
with 100 items per page.
- Q65345564 description "clinical trial" @default.
- Q65345564 description "ensayu clínicu" @default.
- Q65345564 description "klinisch onderzoek" @default.
- Q65345564 description "клінічне випробування" @default.
- Q65345564 name "Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab in Refractory Cancer" @default.
- Q65345564 name "Safety Study of Enoblituzumab" @default.
- Q65345564 type Item @default.
- Q65345564 label "Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab in Refractory Cancer" @default.
- Q65345564 label "Safety Study of Enoblituzumab" @default.
- Q65345564 prefLabel "Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab in Refractory Cancer" @default.
- Q65345564 prefLabel "Safety Study of Enoblituzumab" @default.
- Q65345564 P1050 Q65345564-D315F1CB-0208-4B9B-870A-DFA9D7FA61D5 @default.
- Q65345564 P1132 Q65345564-EE4ED18D-59C3-43E4-A465-23B925E43660 @default.
- Q65345564 P1476 Q65345564-FE66F316-306D-4475-BEE1-517E19DB54C2 @default.
- Q65345564 P17 Q65345564-BF8DF25B-572F-492F-B552-3842C3B4F0CB @default.
- Q65345564 P2899 Q65345564-53EEEA2A-E34E-444A-8DA5-699997669A0A @default.
- Q65345564 P3098 Q65345564-8C44E3C4-25EB-425D-8E65-A47F21CCA23E @default.
- Q65345564 P31 Q65345564-B7C229BE-7544-460C-AE84-67872341368C @default.
- Q65345564 P4844 Q65345564-68C50E39-68A9-4016-988A-EA4C64DFE4DC @default.
- Q65345564 P580 Q65345564-02537AFB-FA52-46E3-90A8-2D419CAD838F @default.
- Q65345564 P582 Q65345564-C968747B-9790-4B07-84AC-E797A807161D @default.
- Q65345564 P6099 Q65345564-A236FEC0-28AC-48D1-A25C-175BBA6643F6 @default.
- Q65345564 P6153 Q65345564-4F2577B6-6CCA-4B64-9274-A7DA8F982CCA @default.
- Q65345564 P6153 Q65345564-5218530D-7869-40EC-BB90-FC645C6872DC @default.
- Q65345564 P6153 Q65345564-63F6CF6F-B2E4-49A5-8B70-8B4E1E3D332B @default.
- Q65345564 P6153 Q65345564-A1F539F0-0745-4E60-AFAC-211A6067958C @default.
- Q65345564 P6153 Q65345564-A48089E8-03A2-4EEF-8D8E-019995B90292 @default.
- Q65345564 P6153 Q65345564-B3937B29-C75A-4B3B-9435-29AB94121D93 @default.
- Q65345564 P6153 Q65345564-D67A00F7-69FD-4F09-B512-7947CED45B69 @default.
- Q65345564 P6153 Q65345564-DA939157-AF57-42E9-9E2A-EA626CEACADE @default.
- Q65345564 P6153 Q65345564-E23E3D20-5B09-410B-BA77-C6D5552C36D9 @default.
- Q65345564 P8363 Q65345564-6E6452BD-2F05-4321-9EE7-79EDBFF79F41 @default.
- Q65345564 P1050 Q180614 @default.
- Q65345564 P1132 "+134" @default.
- Q65345564 P1476 "A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Pembrolizumab in Patients With B7-H3-Expressing Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer and Other B7-H3-Expressing Cancers" @default.
- Q65345564 P17 Q30 @default.
- Q65345564 P2899 "+18" @default.
- Q65345564 P3098 "NCT02475213" @default.
- Q65345564 P31 Q30612 @default.
- Q65345564 P4844 Q13896859 @default.
- Q65345564 P580 "2015-07-01T00:00:00Z" @default.
- Q65345564 P582 "2019-09-01T00:00:00Z" @default.
- Q65345564 P6099 Q5452194 @default.
- Q65345564 P6153 Q1159198 @default.
- Q65345564 P6153 Q235034 @default.
- Q65345564 P6153 Q2415975 @default.
- Q65345564 P6153 Q30286943 @default.
- Q65345564 P6153 Q50039694 @default.
- Q65345564 P6153 Q500606 @default.
- Q65345564 P6153 Q503415 @default.
- Q65345564 P6153 Q7320925 @default.
- Q65345564 P6153 Q7370121 @default.
- Q65345564 P8363 Q78089383 @default.